Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The in vitro development of extended-release solid oral dosage forms.

L J Leeson, D Adair, J Clevenger

    Journal of Pharmacokinetics and Biopharmaceutics
    |October 1, 1985
    PubMed
    Summary

    A new system predicts drug plasma levels from extended-release products using in vitro dissolution and pharmacokinetics. This biorelevant dissolution approach aids in developing effective controlled-release oral dosage forms.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Placental 11β-Hydroxysteroid dehydrogenase type 2 expression: Correlations with birth weight and placental metal concentrations.

    Placenta·2015
    Same author

    PP087. Deep trial secondary analysis: Digoxin immune fab fragment treatment has additional benefits in endogenous digitalis-like factor positive preeclamptic women.

    Pregnancy hypertension·2015
    Same author

    Placental concentrations of bisphenol A and birth weight from births in the Southeastern U.S.

    Placenta·2014
    Same author

    The Concise Guide to PHARMACOLOGY 2013/14: overview.

    British journal of pharmacology·2014
    Same author

    Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion.

    Mucosal immunology·2013
    Same author

    Real-life experience of managing vulval erosive lichen planus: a case-based review and U.K. multicentre case note audit.

    The British journal of dermatology·2012

    Area of Science:

    • Pharmacokinetics and Drug Delivery
    • Pharmaceutical Sciences

    Background:

    • Developing extended-release (ER) oral dosage forms requires predicting in vivo performance.
    • Traditional methods often lack precision in forecasting the plasma drug concentration-time profile.

    Purpose of the Study:

    • To introduce a novel system for developing extended-release products.
    • To predict the complete plasma level-time curve of controlled-release oral dosage forms.

    Main Methods:

    • The system, termed "biorelevant dissolution," integrates in vitro dissolution data.
    • It utilizes pharmacokinetic parameters of the drug.
    • A classical pharmacokinetic model is employed for simulation.

    Main Results:

    • The biorelevant dissolution system successfully predicts the plasma level-time curve.

    Related Experiment Videos

  • The approach demonstrates applicability through pertinent examples.

    • Conclusions:

    • Biorelevant dissolution offers a robust method for designing and evaluating extended-release oral dosage forms.
    • This predictive system enhances the development of controlled-release medications.